BRPI0807456A2 - Membro de ligação isolado, membros de ligação isolado ou domínio vh e vl, molécula de ácido nucléico isolada, célula hospedeira, método para produzir um membro de ligação isolado, composição farmacêutica, e, uso da composição - Google Patents

Membro de ligação isolado, membros de ligação isolado ou domínio vh e vl, molécula de ácido nucléico isolada, célula hospedeira, método para produzir um membro de ligação isolado, composição farmacêutica, e, uso da composição

Info

Publication number: BRPI0807456A2
Authority: BR; Brazil
Prior art keywords: isolated; connection member; computer use; isolated connection; domain
Prior art date: 2007-02-15

Application number

BRPI0807456-9A2A

Other languages

English (en)

Inventor

Duncan Cochrane

Suzanne Cohen

Claire Louise Dobson

Per-Olof Fredrik Eriksson

Phillip David Monk

Karin Von-Wachenfeldt

Original Assignee

Astrazeneca Ab

Medimmune Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-15

Filing date

2008-02-15

Publication date

2015-01-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0807456(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-02-15 Application filed by Astrazeneca Ab, Medimmune Ltd filed Critical Astrazeneca Ab

2015-01-27 Publication of BRPI0807456A2 publication Critical patent/BRPI0807456A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pulmonology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Biotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Physics & Mathematics (AREA)
Rheumatology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Dermatology (AREA)

BRPI0807456-9A2A 2007-02-15 2008-02-15 Membro de ligação isolado, membros de ligação isolado ou domínio vh e vl, molécula de ácido nucléico isolada, célula hospedeira, método para produzir um membro de ligação isolado, composição farmacêutica, e, uso da composição BRPI0807456A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US90130407P	2007-02-15	2007-02-15
PCT/GB2008/000510 WO2008099178A2 (en)	2007-02-15	2008-02-15	Binding members for ige molecules

Publications (1)

Publication Number	Publication Date
BRPI0807456A2 true BRPI0807456A2 (pt)	2015-01-27

Family

ID=39639279

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0807456-9A2A BRPI0807456A2 (pt)	2007-02-15	2008-02-15	Membro de ligação isolado, membros de ligação isolado ou domínio vh e vl, molécula de ácido nucléico isolada, célula hospedeira, método para produzir um membro de ligação isolado, composição farmacêutica, e, uso da composição

Country Status (19)

Country	Link
US (3)	US7959917B2 (pt)
EP (2)	EP2620452A1 (pt)
JP (1)	JP2010518815A (pt)
KR (1)	KR20100014790A (pt)
CN (1)	CN101675079A (pt)
AR (1)	AR065368A1 (pt)
AU (1)	AU2008216008B2 (pt)
BR (1)	BRPI0807456A2 (pt)
CA (1)	CA2677748A1 (pt)
CL (1)	CL2008000478A1 (pt)
IL (1)	IL200046A0 (pt)
MX (1)	MX2009008410A (pt)
PE (1)	PE20090688A1 (pt)
RU (2)	RU2466140C2 (pt)
SG (1)	SG178767A1 (pt)
TW (1)	TW200844114A (pt)
UY (1)	UY30927A1 (pt)
WO (1)	WO2008099178A2 (pt)
ZA (1)	ZA200905210B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8105611B2 (en) *	2005-06-17	2012-01-31	Allergan, Inc.	Treatment of autoimmune disorder with a neurotoxin
AR065368A1 (es) *	2007-02-15	2009-06-03	Astrazeneca Ab	Anticuerpos para moleculas de ige
WO2008099188A1 (en) *	2007-02-15	2008-08-21	Astrazeneca Ab	Binding members for ige molecules
CN101932593B (zh) *	2008-01-29	2014-08-20	埃博灵克斯股份有限公司	稳定蛋白和多肽的方法
US10017762B2 (en) *	2010-11-24	2018-07-10	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Compositions and methods for treating or preventing lupus
WO2014087010A1 (en) *	2012-12-07	2014-06-12	Ablynx N.V.	IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE
TWI691512B (zh)	2015-02-20	2020-04-21	日商橘生藥品工業股份有限公司	Ｆｃ融合高親和性ＩｇＥ受體α鏈
US20180051069A1 (en) *	2015-03-06	2018-02-22	The General Hospital Corporation	Compositions and methods for treating allergic inflammation
SG11202005863TA (en)	2018-01-12	2020-07-29	Gi Innovation Inc	Composition comprising probiotics and polypeptide having binding affinity for ige and use thereof
US20220259290A1 (en) *	2019-07-24	2022-08-18	Japan Science And Technology Agency	Innovative production technique for antibody-enzyme
TWI740647B (zh) *	2020-09-15	2021-09-21	宏碁股份有限公司	疾病分類方法及疾病分類裝置
ES2980622T3 (es)	2020-09-19	2024-10-02	Esspen Gmbh	Tomógrafo computarizado y procedimiento para manejar un tomógrafo computarizado
EP4306956A1 (de) *	2022-07-15	2024-01-17	Justus-Liebig-Universität Gießen	Verfahren zum in-vitro nachweis antigen-spezifischer ige verursacht durch eine infektion mit parasiten oder pilzen

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
JPS61134325A (ja)	1984-12-04	1986-06-21	Teijin Ltd	ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
WO1989006138A1 (en)	1987-12-31	1989-07-13	Tanox Biosystems, Inc.	UNIQUE ANTIGENIC EPITOPES ON IgE-BEARING B LYMPHOCYTES
US5185243A (en)	1988-08-25	1993-02-09	Syntex (U.S.A.) Inc.	Method for detection of specific nucleic acid sequences
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ES2107454T3 (es)	1990-01-23	1997-12-01	Tanox Biosystems Inc	Segmentos extracelulares de peptidos de anclaje de la inmunoglobulina ige humana, y anticuerpos especificos para los mismos.
GB9206318D0 (en)	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5962255A (en)	1992-03-24	1999-10-05	Cambridge Antibody Technology Limited	Methods for producing recombinant vectors
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
US6492160B1 (en)	1991-05-15	2002-12-10	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
ES2193136T3 (es)	1991-08-14	2003-11-01	Genentech Inc	Variantes de inmunoglubina para receptores especificos de fc epsilon.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
ATE463573T1 (de)	1991-12-02	2010-04-15	Medimmune Ltd	Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5872215A (en)	1991-12-02	1999-02-16	Medical Research Council	Specific binding members, materials and methods
GB9203459D0 (en)	1992-02-19	1992-04-08	Scotgen Ltd	Antibodies with germ-line variable regions
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5552537A (en)	1993-03-24	1996-09-03	The Regents Of The University Of California	IgE isoforms and methods of use
ZA966075B (en)	1995-07-27	1998-01-19	Genentech Inc	Protein formulation.
US5814468A (en)	1996-03-27	1998-09-29	Coulter International Corp.	Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
US5994511A (en)	1997-07-02	1999-11-30	Genentech, Inc.	Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en)	1997-07-02	2001-01-09	Genentech, Inc.	Anti-IgE antibodies and method of improving polypeptides
DK1137941T4 (da)	1998-12-10	2014-01-06	Brystol Myers Squibb Company	Protein-scaffolds til antistof-mimetika og andre bindingsproteiner
CZ20013082A3 (cs) *	1999-02-25	2002-02-13	Smithkline Beecham Biologicals S. A.	Peptid
WO2002088171A2 (en)	2001-04-26	2002-11-07	Avidia Research Institute	Combinatorial libraries of monomer domains
US20030157561A1 (en)	2001-11-19	2003-08-21	Kolkman Joost A.	Combinatorial libraries of monomer domains
IL166244A0 (en)	2001-07-12	2006-01-15	Jefferson Foote	Super humanized antibodies
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
US7658924B2 (en) *	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
WO2004000217A2 (en)	2002-06-20	2003-12-31	The Trustees Of The University Of Pennsylvania	Vaccines for suppressing ige-mediated allergic disease and methods for using the same
ES2575547T3 (es)	2003-02-01	2016-06-29	Tanox, Inc.	Anticuerpos anti-IgE de humano de alta afinidad
US20050169909A1 (en) *	2004-02-02	2005-08-04	Sanjaya Singh	Identification of novel IgE epitopes
KR20070008578A (ko) *	2004-02-02	2007-01-17	타녹스 인코퍼레이티드	신규한 ＩｇＥ 에피토프의 확인
WO2008099188A1 (en)	2007-02-15	2008-08-21	Astrazeneca Ab	Binding members for ige molecules
AR065368A1 (es) *	2007-02-15	2009-06-03	Astrazeneca Ab	Anticuerpos para moleculas de ige
US9209965B2 (en)	2014-01-14	2015-12-08	Microsemi Semiconductor Ulc	Network interface with clock recovery module on line card

2008
- 2008-01-15 AR ARP080100654A patent/AR065368A1/es unknown
- 2008-02-14 TW TW097105156A patent/TW200844114A/zh unknown
- 2008-02-14 PE PE2008000321A patent/PE20090688A1/es not_active Application Discontinuation
- 2008-02-14 CL CL200800478A patent/CL2008000478A1/es unknown
- 2008-02-15 MX MX2009008410A patent/MX2009008410A/es active IP Right Grant
- 2008-02-15 SG SG2012009031A patent/SG178767A1/en unknown
- 2008-02-15 US US12/032,061 patent/US7959917B2/en not_active Expired - Fee Related
- 2008-02-15 AU AU2008216008A patent/AU2008216008B2/en not_active Ceased
- 2008-02-15 RU RU2009134227/10A patent/RU2466140C2/ru not_active IP Right Cessation
- 2008-02-15 KR KR1020097017009A patent/KR20100014790A/ko not_active Ceased
- 2008-02-15 WO PCT/GB2008/000510 patent/WO2008099178A2/en not_active Ceased
- 2008-02-15 JP JP2009549468A patent/JP2010518815A/ja active Pending
- 2008-02-15 US US12/527,169 patent/US8389704B2/en active Active
- 2008-02-15 EP EP13155314.1A patent/EP2620452A1/en not_active Withdrawn
- 2008-02-15 EP EP08709401A patent/EP2115007A2/en not_active Withdrawn
- 2008-02-15 CN CN200880012211A patent/CN101675079A/zh active Pending
- 2008-02-15 UY UY30927A patent/UY30927A1/es not_active Application Discontinuation
- 2008-02-15 CA CA002677748A patent/CA2677748A1/en not_active Abandoned
- 2008-02-15 BR BRPI0807456-9A2A patent/BRPI0807456A2/pt not_active IP Right Cessation
2009
- 2009-07-23 IL IL200046A patent/IL200046A0/en unknown
- 2009-07-24 ZA ZA200905210A patent/ZA200905210B/xx unknown
2012
- 2012-07-19 RU RU2012130841/10A patent/RU2012130841A/ru not_active Application Discontinuation
- 2012-11-16 US US13/679,080 patent/US20140127212A1/en not_active Abandoned

Also Published As

Publication number	Publication date
RU2009134227A (ru)	2011-03-20
EP2115007A2 (en)	2009-11-11
US8389704B2 (en)	2013-03-05
CA2677748A1 (en)	2008-08-21
TW200844114A (en)	2008-11-16
EP2620452A1 (en)	2013-07-31
WO2008099178A3 (en)	2008-10-16
RU2466140C2 (ru)	2012-11-10
SG178767A1 (en)	2012-03-29
MX2009008410A (es)	2009-08-18
US20140127212A1 (en)	2014-05-08
AU2008216008B2 (en)	2012-07-05
JP2010518815A (ja)	2010-06-03
AR065368A1 (es)	2009-06-03
UY30927A1 (es)	2008-09-30
KR20100014790A (ko)	2010-02-11
RU2012130841A (ru)	2014-01-27
CL2008000478A1 (es)	2008-10-17
PE20090688A1 (es)	2009-07-15
US20090060919A1 (en)	2009-03-05
CN101675079A (zh)	2010-03-17
AU2008216008A1 (en)	2008-08-21
US20100150904A1 (en)	2010-06-17
US7959917B2 (en)	2011-06-14
WO2008099178A2 (en)	2008-08-21
ZA200905210B (en)	2010-03-31
IL200046A0 (en)	2010-04-15

Legal Events

Date	Code	Title	Description
2015-12-01	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 7A ANUIDADE.
2016-03-29	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0807456A2 (pt)	2015-01-27	Membro de ligação isolado, membros de ligação isolado ou domínio vh e vl, molécula de ácido nucléico isolada, célula hospedeira, método para produzir um membro de ligação isolado, composição farmacêutica, e, uso da composição
BRPI0922106A2 (pt)	2018-10-16	anticorpo monoclonal isolado, molécula de ácido nucleico isolada, célula hospedeira, método para produzir um anticorpo monoclonal isolado, composição farmacêutica, e, uso da composição
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
BRPI0819936A2 (pt)	2015-05-26	Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
BRPI0819085A2 (pt)	2015-04-22	Sistema para uso com produção de hidrocarbonetos, e, método associado com produção de hidrocarbonetos
BRPI0822099A2 (pt)	2017-05-23	membro de ligação isolado, uso de um membro de ligação isolado, método parav tratar um distúrbio, molécula de ácido nucléico isolada, célula hospedeira, e, método para produzir um membro de ligação
BRPI0816426A2 (pt)	2015-03-03	Dispositivo para investigar uma molécula, método para investigar uma molécula, substrato adequado para uso no dispositivo para investigar moléculas, método para sequenciar um ácido nucléico.
BRPI0807269A2 (pt)	2014-04-29	"anticorpo antagonista isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, composição, método de tratamento, método para tratamento, método para reduzir a severidade da asma, método para produzir um anticorpo, hibridoma, uso do anitocrpo, método para detectar ox40, kits e aparelhos médicos"
BRPI0816330A2 (pt)	2015-04-14	Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
BRPI0923500A2 (pt)	2018-05-29	uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
BRPI0717768A2 (pt)	2013-11-05	Anticorpo, epítipo, seqüência de dna isolada, vetor de clonagem ou expressão, célula hospedeira, processo para a produção do anticorpo, composição farmacêutica, e, uso de um anticorpo
BRPI0814781A2 (pt)	2014-10-21	Proteína, sequência de ácido nucleico, método para a produção de ácido itacônico, vetor, célula hospedeira, e, uso de um ácido cis-aconítico
BRPI0817265A2 (pt)	2015-06-16	Vacina de rna, uso de pelo menos uma molécula de rna, e, molécula de rna isolada
BRPI0907531A2 (pt)	2018-11-06	sistema de pipetagem e método para medição de viscosidade
BR112013015508A2 (pt)	2016-10-11	molécula de anticorpo isolada para il-18 humana, composição, uso de uma molécula de anticorpo, molécula de ácido nucleico isolada, célula hospedeira, e, métodos para produzir um anticorpo e para medir il-18
BRPI0916964A2 (pt)	2015-11-24	polipetídeo, anticorpo, ácido nucléico, vetor, célula hospedeira, método para produzir um polipeptídeo, composição e uso do polipeptídeo
BRPI0819338A2 (pt)	2015-05-19	Preparações, métodos e kits úteis para o tratamento de tosse
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BRPI0924177A2 (pt)	2015-08-18	Polipeptídeos, seu método de preparação, sua composição, sequência de nucleotídeo e uso
BR112014017518A2 (pt)	2018-09-04	anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
BRPI0922742A2 (pt)	2016-01-05	adesivo ou selante, processo para preparar um adesivo ou selante, e, uso do adesivo ou selante.
BRPI0920955A2 (pt)	2016-01-05	processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
BRPI0810211A2 (pt)	2014-10-21	Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.